Hormonal therapy in women, thromboembolic complications and laboratory characteristics of the hemostasis system for personalized solutions
https://doi.org/10.18705/2782-3806-2023-3-4-52-58
Abstract
The use of hormonal drugs for contraception and menopausal replacement therapy is widespread throughout the world. However, the use of these drugs is associated with an increased risk of thromboembolic complications (TEO). At present, it has been established that the most important cause of feasibility study is the initial, sometimes hidden, violations of the hemostasis system, predisposing to increased blood clotting and thrombosis. Their timely identification helps to personalize the use of the necessary hormonal therapy.
About the Authors
O. N. Startseva
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Startseva Olga N. - PhD (in Biol.), Biologist, Laboratory of Clinical Chemistry of the Department of Laboratory Diagnostics
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
T. V. Vavilova
Nikiforov Russian Center of Emergency and Radiation Medicine; Almazov National Medical Research Centre
Russian Federation
Russian Federation
Vavilova Tatiana V.- Dr. Sc. (Med.), Professor, Head of Laboratory and Genetic Education Department
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
N. N. Zybina
Nikiforov Russian Center of Emergency and Radiation Medicine; Almazov National Medical Research Centre
Russian Federation
Russian Federation
Zybina Natalia N. - Dr. Sc. (in Biol.), Head of Department of clinical laboratory diagnostics
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
References
1. Сотникова Л.С. Возможности терапии и профилактики тромбозов на фоне гормональной терапии в гинекологии / Л. С. Сотникова, Е. В. Голубятникова // Гинекология. Эндокринология. 2017. № 9. С. 27–32.
2. Вереина Н.К. Факторы риска венозных и артериальных тромбозов у молодых женщин вне беременности/ Н. К. Вереина, Т. В. Мовчан, В. С. Чулков // Атеротромбоз. 2020. № 1. С. 18– 32.
3. Баландина А.Н. Тромбодинамика: новый подход к диагностике нарушений системы гемостаза / А. Н. Баландина, Е. Н. Кольцова, А. М. Шибеко и др.// Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2018; 17 (4). С. 114–126.
4. Хамани Н.М. Ретроспективный анализ факторов риска тромботических осложнений при приеме комбинированных оральных контрацептивов / Н. М. Хамани, Р. А. Саидова, И. В. Хамани и др. // Акушерство и гинекология. 2019. № 6. С. 108–113.
5. Chen M. Contraception for women with medical problems / Chen M., Culwell K. // Glob. libr. women’s med., 2015 (ISSN: 1756-2228) 2015. DOI 10.3843/GLOWM.10382.
6. Kruijf P De. A New Pharmacodynamic test to Evaluate effects of oral contraceptives on coagulation [abstract] / de Kruijf P, Naji S, Krijnen C, Jespersen J, Kluft C. A [abstract]. // Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-new-pharmacodynamic-test-to-evaluate-effects-of-oral-contraceptives-on-coagulation/
7. Lidegaard О. Oral contraceptives and venous thromboembolism: a live-year national case-control studi / Lidegaard O., Edstrom B., Kreiner S. // Contraception. 2002; 65(3):187–96.
Review
For citations:
Startseva O.N., Vavilova T.V., Zybina N.N. Hormonal therapy in women, thromboembolic complications and laboratory characteristics of the hemostasis system for personalized solutions. Russian Journal for Personalized Medicine. 2023;3(4):52-58. (In Russ.) https://doi.org/10.18705/2782-3806-2023-3-4-52-58
Views:
178
Email this article 